Prevents itching associated with allergic conjunctivitis. ANDA 90951, held by Somerset Therapeutics. Epinastine Hydrochloride.
As of Nov 21, 2026, ANDA 90951 (Epinastine Hydrochloride), held by Somerset Therapeutics, was first approved by FDA on Oct 31, 2011, with 1 approved supplement and 0 published complete response letters.
Epinastine HCl ophthalmic solution is an H 1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 31, 2011 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Epinastine Hydrochloride0.05% · solution/drops;ophthalmic | Epinastine Hydrochloride | Rx |
| Aug 18, 2015 | Supplement 3Labeling · Standard review | Approved | None posted |
| Oct 31, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters